Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
Information source: University Hospital, Caen
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cirrhosis
Intervention: L-carnitine (Drug); Lactulose (Drug)
Sponsored by: University Hospital, Caen
Official(s) and/or principal investigator(s):
Marie-Astrid PIQUET, Principal Investigator, Affiliation: University Hospital, Caen
Thong DAO, Study Director, Affiliation: University Hospital, Caen
The project will improve scientific knowledge regarding a recent law applying potentially to
every french driver. It will give for the first time an indication on the impact of alerting
treatments on driving risks. It will reinforce the links between different research
environments (sleep physiopathology, clinical research, cognitive neurosciences, drivers
supervision, virtual reality, pharmacology) among the "Réseau Eveil Sommeil Attention et
Transports" (RESAT) network.
Official title: Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. Impact of Lactulose and Carnitine Treatment.
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: Sleep latency during Maintenance of Wakefulness Test (MWT)
Nocturnal sleep quality and quantity will be measured by Polysomnography (PSG).
Nocturnal sleep quality and quantity measured by Actimetry.
Excessive daytime sleepiness is responsible of 20% of traffic accidents and 2/3 of truck
accidents on French Freeways. Since the publication of a new law (2005 december 28th -
Official Journal) regulating fitness to drive, the Maintenance of Wakefulness Test (MWT) is
now mandatory to evaluate driving skills of patients suffering of excessive daytime
sleepiness. The MWT has shown a good predictability of driving handicap on simulators in
patients suffering from obstructive sleep apnea syndrome. Nevertheless no study has proven
yet the predictability of the MWT regarding real and simulated driving in patients suffering
from hepatic encephalopathy. Furthermore, even if therapeutic drugs significantly improve
MWT scores there is no data available concerning the impact of these drugs on fitness to
drive. Lactulose, a treatment of hepatic encephalopathy, has not been tested as a counter
measure to driving impairment. This lack of knowledge is a major handicap to evaluate
driving skills of treated patients suffering from excessive daytime sleepiness. The main
objective of our project is to test the predictive value of the MWT on real and simulated
driving performances in untreated and treated sleepy patients suffering from hepatic
Minimum age: 18 Years.
Maximum age: 80 Years.
- Cirrhosis proved by histologic or clinico-biologics criteria, whatever its severity,
its stability defined by a child stable score (variation < 2 points for the last
month) without any other disease which could be responsible of excessive daytime
- driver's licence since at least 2 years
- driving more than 2000 Km/year
- registered to French national health and pensions organization
- having given their written light agreement in order to participate in the study.
- Night workers
- neurologic disease
- recent strong complication (< 30 days)
- recent antibiotics or lactulose intake
- substance abusers (alcohol)
- hepatoma more than 5 cm
- disorder associated which engaged life prognostic in a short time
- glycemia fasted > 8 mmol/l
- haemoglobin < 10g/l
- neurologic or psychiatric disorders associated which affect superiors functions,
- hepatic encephalopathy stage 3 or 4
- having participated in a clinical study during the last 6 months
- drugs abusers
- unable to drive.
Locations and Contacts
University Hospital of Caen, Caen 14033, France; Recruiting
Marie-Astrid PIQUET, Phone: +33(0)2.31.06.52.00, Email: firstname.lastname@example.org
Pierre DENISE, Phone: +33(0)2.31.06.82.14, Email: email@example.com
Marie-Astrid PIQUET, Principal Investigator
Starting date: September 2009
Last updated: August 31, 2012